Myeloproliferative disease in children is rare. In the early published reports discussion focused on idiopathic myelofibrosis.' Considerable effort has since been taken to differentiate classic from juvenile chronic myeloid leukaemia (CML)2 and juvenile CML from the myeloproliferative syndrome associated with monosomy 7. The association of Epstein-Barr virus with myeloproliferative disorders and monosomy 7 has also been noted. 4 More recently a myeloproliferative disorder associated with eosinophilia and a translocation between chromosomes I and 5 has been described. 5 The other forms of myeloproliferative disease are often dismissed in a single sentence. We report here all children in whom a diagnosis of myeloproliferative disease has been made since 1980 in the northern region of England.
Patients and methods
All cases of myeloproliferative disease diagnosed in children under the age of 15 since 1980 were recorded. The cases came to light either by direct referral to one of the Newcastle hospitals, by notification to the Northern Region Children's Malignant Disease Registry, and after direct contact with the haematologists of the northern region. All pathological material was reviewed by one of us (MMR). Bone marrow aspirates and trephine biopsy specimens were obtained from all children, but the biopsy specimen from one child with CML was inadequate. Cytogenetic analysis was performed on peripheral blood in this child and on bone marrow samples from all others. The incidence was calculated using the Office of Population Censuses and Surveys (OPCS) mid-year estimates.6
Accepted for publication 17 Thus while there were no difficulties in making a firm diagnosis in the five children with CML, apart from having to resort to molecular investigations in one, it was more difficult in the other three. Case 1, however, clearly had essential thrombocythaemia and it would be unreasonable to argue that the persistent thrombocytosis and marrow expansion, still present three years after initial presentation, were reactive. Cases 2 and 3 had long standing splenomegaly and myeloid hyperplasia. One, case 3, also had the classic peripheral blood appearances of myelofibrosis, though neither had clinically important reticulin in the marrow. While Pelger cells may sometimes be found in the peripheral blood of patients with myeloproliferative disease, they are not always present, and prominent dyserythropoiesis is usually a feature of myelodysplastic rather than myeloproliferative disease. Up to one third ofpatients with agnogenic myeloid metaplasia have only minimal or no increase in reticulin in their marrow. 7 The study dates from 1980: before that date no case of myeloproliferative disease other than CML had been recognised in a child in the northern region. These cases represent all subsequently recognised myeloproliferative disorders ofchildren in our region. It is possible that some await recognition and others may have died unrecognised. It is unlikely that a recognisable myeloproliferative disorder is hidden behind a diagnosis of leukaemia, as one of us (MMR) Myeloproliferative disease in children 885 has reviewed the pathological material or case records of all cases of leukaemia occurring in patients under the age of 25 in the northern region since 1968, as part of the recommendations of the committee chaired by Sir Douglas Black, which has been investigating the incidence of leukaemia in our region.
Little is known of the incidence of myeloproliferative diseases in a defined population. The Manchester registry8 recorded an incidence of 0.5 cases and the Greater Delaware Valley registry9 0-86 cases of CML per million white children per year. The present study suggests an annual incidence of about one case of classic CML per million children and a somewhat lower rate for the other heterogeneous group of diseases. In the 15 years from 1968 to 1982 only four cases of CML were recorded by the Northern Region Children's Malignant Disease Registry'( 0.45 cases/106 children/year), none of which is included in the present series. The apparent increase in incidence may be spurious. Nevertheless, classic CML is the single most common myeloproliferative disease in childhood. If the incidence of these diseases is similar elsewhere in the United Kingdom, well over 100 cases ofchildhood myeloproliferative disease have occurred in the country since 1980. It is striking that no case ofjuvenile CML has ever been recognised in our region, despite its well described clinical and laboratory features. This contrasts sharply with the experience of Hardisty et al2 and their review of the literature.
The behaviour of myeloproliferative diseases in children and young people remains unclear, with the exception of classic and juvenile CML. For example, does essential thrombocythaemia behave in the same way as in elderly patients? The single biggest series of young patients with this disorder comes from the Mayo Clinic," the youngest ofwhich was aged 15. The stability and lack of clinical problems in the Mayo Clinic series suggests a course of masterly inaction, at least initially, but this recommendation is based on small numbers. Although death has usually rapidly followed diagnosis of myelofibrosis in children, this is not always the case.'2 The theoretical risk of transformation to acute leukaemia in children with "adult" types of myeloproliferative disease seems to be less than in CML'3; the three children without CML described here have been affected for at least three, eight, and 17 years without any sign of transformation.
In summary, although myeloproliferative diseases are rare in childhood, classic CML is by far the most common; other "adult" diseases do occur; and the specific childhood diseases of juvenile CML and monosomy 7 myeloproliferation are very rare. We suspect that haematologists and pathologists are reluctant to make diagnoses of "adult" types of myeloproliferative disease other than CML and that juvenile CML and other clinically similar disorders have been over-represented in the literature because of their unique features. Registries of malignant diseases ofchildren will often fail to "capture" these diseases as the term leukaemia is not always attached to the diagnosis. Unless myeloproliferative disorders are collected by registries in the same systematic way as leukaemia and other cancers their natural history will remain obscure, and haematologists and paediatricians will have little information on which to base their therapeutic advice.
